Fierce Biotech
Novartis pays Synnovation $2B upfront for breast cancer program as rivals circle
Novartis has struck a deal to buy Synnovation Therapeutics’ pan-mutant‑selective PI3Kα inhibitor for $2 billion upfront, securing an asset that could defend its breast cancer franchise from challengers including Eli Lilly.